U.S. markets open in 3 hours 48 minutes
  • S&P Futures

    4,456.25
    +10.50 (+0.24%)
     
  • Dow Futures

    34,820.00
    +146.00 (+0.42%)
     
  • Nasdaq Futures

    15,305.25
    -13.50 (-0.09%)
     
  • Russell 2000 Futures

    2,255.60
    +11.60 (+0.52%)
     
  • Crude Oil

    74.98
    +1.00 (+1.35%)
     
  • Gold

    1,750.00
    -1.70 (-0.10%)
     
  • Silver

    22.37
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1703
    -0.0015 (-0.13%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    17.76
    -0.87 (-4.67%)
     
  • GBP/USD

    1.3694
    +0.0013 (+0.10%)
     
  • USD/JPY

    110.9420
    +0.2570 (+0.23%)
     
  • BTC-USD

    43,556.13
    +875.32 (+2.05%)
     
  • CMC Crypto 200

    1,088.22
    -14.84 (-1.35%)
     
  • FTSE 100

    7,080.28
    +28.80 (+0.41%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

How Many Sio Gene Therapies Inc. (NASDAQ:SIOX) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Sio Gene Therapies Inc. (NASDAQ:SIOX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

Sio Gene Therapies is a smaller company with a market capitalization of US$171m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Sio Gene Therapies.

Check out our latest analysis for Sio Gene Therapies

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Sio Gene Therapies?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Sio Gene Therapies. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Sio Gene Therapies, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It looks like hedge funds own 7.9% of Sio Gene Therapies shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Roivant Sciences Ltd. is currently the largest shareholder, with 27% of shares outstanding. With 7.9% and 4.6% of the shares outstanding respectively, Suvretta Capital Management, LLC and Consonance Capital Management LP are the second and third largest shareholders.

We did some more digging and found that 8 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Sio Gene Therapies

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own less than 1% of Sio Gene Therapies Inc.. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It seems the board members have no more than US$697k worth of shares in the US$171m company. I generally like to see a board more invested. However it might be worth checking if those insiders have been buying.

General Public Ownership

With a 43% ownership, the general public have some degree of sway over Sio Gene Therapies. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 27%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Sio Gene Therapies better, we need to consider many other factors. Take risks for example - Sio Gene Therapies has 3 warning signs (and 2 which are significant) we think you should know about.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.